Structural basis of ligand interactions of the large extracellular domain of tetraspanin CD81

Journal of Virology

Volumn 86, Issue 18, 2012, Pages 9606-6616

  Rajesh, Sundaresan ^a   Sridhar, Pooja ^a   Tews, Birke Andrea ^b   Fénéant, Lucie ^b   Cocquerel, Laurence ^b   Ward, Douglas G ^a   Berditchevski, Fedor ^a   Overduin, Michael ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD81 ANTIGEN; GLYCOPROTEIN E2;

ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; HEPATITIS C; HEPATITIS C VIRUS; LIGAND BINDING; MEMBRANE BINDING; MOLECULAR RECOGNITION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SECONDARY STRUCTURE; STRUCTURE ANALYSIS; VIRUS CELL INTERACTION; VIRUS NEUTRALIZATION;

ANTIGENS, CD81; BINDING SITES; HEK293 CELLS; HEPACIVIRUS; HEPATOCYTES; HOST-PATHOGEN INTERACTIONS; HUMANS; LIGANDS; MODELS, MOLECULAR; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PROTEIN INTERACTION DOMAINS AND MOTIFS; RECEPTORS, VIRUS; RECOMBINANT PROTEINS; VIRAL ENVELOPE PROTEINS;

HEPATITIS C VIRUS; MAMMALIA;

EID: 84866159878     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00559-12     Document Type: Article

References (56)

1. Akazawa D, et al. 2007. CD81 expression is important for the permissiveness of Huh7 cell clones for heterogeneous hepatitis C virus infection. J. Virol. 81:5036-5045.
2. Albecka A, et al. 2011. Identification of new functional regions in hepatitis C virus envelope glycoprotein E2. J. Virol. 85:1777-1792.
3. Aricescu AR, Lu W, Jones EY. 2006. A time- and cost-efficient system for high-level protein production in mammalian cells. Acta Crystallogr. D Biol. Crystallogr. 62:1243-1250.
4. Baldick CJ, et al. 2010. A novel small molecule inhibitor of hepatitis C virus entry. PLoS Pathog. 6:e1001086. doi:10.1371/journal.ppat.1001086.
5. Bartosch B, Dubuisson J. 2010. Recent advances in hepatitis C virus cell entry. Viruses 2:692-709.
6. Berjanskii M, Wishart D. 2008. Application of the random coil index to studying protein flexibility. J. Biomol. NMR 40:31-48.
7. Bertaux C, Dragic T. 2006. Different domains of CD81 mediate distinct stages of hepatitis C virus pseudoparticle entry. J. Virol. 80:4940-4948.
8. Bradbury L, Kansas G, Levy S, Evans R, Tedder T. 1992. The CD19/ CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 molecules. J. Immunol. 149:2841-2850.
9. Brown PH, Schuck P. 2006. Macromolecular size-and-shape distributions by sedimentation velocity analytical ultracentrifugation. Biophys. J. 90:4651-4661.
10. Cao J, et al. 2007. Selection of a phage-displayed peptide recognized by monoclonal antibody directed blocking the site of hepatitis C virus E2 for human CD81. J. Microbiol. Methods 68:601-604.
11. Cao J, et al. 2003. Phage display selection on whole cells yields a small peptide specific for HCV receptor human CD81. Cell Res. 13:473-479.
12. Charrin S, et al. 2003. EWI-2 is a new component of the tetraspanin web in hepatocytes and lymphoid cells. Biochem. J. 373:409-421.
13. Charrin S, et al. 2003. A physical and functional link between cholesterol and tetraspanins. Eur. J. Immunol. 33:2479-2489.
14. Chen C. 2007. Some pharmacokinetic aspects of the lipophilic terfenadine and zwitterionic fexofenadine in humans. Drugs R D 8:301-314.
15. Delaglio F, et al. 1995. NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J. Biomol. NMR 3:277-293.
16. Drummer HE, Wilson KA, Poumbourios P. 2005. Determinants of CD81 dimerization and interaction with hepatitisCvirus glycoprotein E2. Biochem. Biophys. Res. Commun. 328:251-257.
17. Drummer HE, Wilson KA, Poumbourios P. 2002. Identification of the hepatitis C virus E2 glycoprotein binding site on the large extracellular loop of CD81. J. Virol. 76:11143-11147.
18. Flint M, et al. 1999. Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. J. Virol. 73:6235-6244.
19. Flint M, et al. 2006. Diverse CD81 proteins support hepatitis C virus infection. J. Virol. 80:11331-11342.
20. Geisert EE, et al. 2002. Increased brain size and glial cell number in CD81-null mice. J. Comp. Neurol. 453:22-32.
21. Hassuna N, Monk PN, Moseley GW, Partridge LJ. 2009. Strategies for targeting tetraspanin proteins: potential therapeutic applications in microbial infections. BioDrugs 23:341-359.
22. Hemler ME. 2005. Tetraspanin functions and associated microdomains. Nat. Rev. Mol. Cell Biol. 6:801-811.
23. Higginbottom A, et al. 2000. Identification of amino acid residues in CD81 critical for interaction with hepatitis C virus envelope glycoprotein E2. J. Virol. 74:3642-3649.
24. Holzer M, et al. 2008. Identification of terfenadine as an inhibitor of human CD81-receptor HCV-E2 interaction: synthesis and structure optimization. Molecules 13:1081-1110.
25. Holzer M, et al. 2008. Microwave-assisted syntheses of amino acid ester substituted benzoic acid amides: potential inhibitors of human CD81-receptor HCV-E2 interaction. Open Med. Chem. J. 2:21-25.
26. Holzer M, et al. 2008. Structural modifications of salicylates: inhibitors of human CD81-receptor HCV-E2 interaction. Arch. Pharm. 341:478-484.
27. Jamshad M, et al. 2008. Structural characterization of recombinant human CD81 produced in Pichia pastoris. Protein Expr. Purif. 57:206-216.
28. Kami K, Rajesh S, Overduin M. 2009. Phospholipid-interacting proteins by solution-state NMR spectroscopy, p 291-306. In Lipid signaling protocols. Humana Press, Totowa, NJ.
29. Kitadokoro K, et al. 2001. CD81 extracellular domain 3D structure: insight into the tetraspanin superfamily structural motifs. EMBO J. 20:12-18.
30. Kitadokoro K, et al. 2002. Subunit association and conformational flexibility in the head subdomain of human CD81 large extracellular loop. Biol. Chem. 383:1447-1452.
31. Korzhnev DM, Religa TL, Banachewicz W, Fersht AR, Kay LE. 2010. A transient and low-populated protein-folding intermediate at atomic resolution. Science 329:1312-1316.
32. Koutsoudakis G, Herrmann E, Kallis S, Bartenschlager R, Pietschmann T. 2007. The level of CD81 cell surface expression is a key determinant for productive entry of hepatitis C virus into host cells. J. Virol. 81:588-598.
33. Krey T, et al. 2010. The disulfide bonds in glycoprotein E2 of hepatitis C virus reveal the tertiary organization of the molecule. PLoS Pathog. 6:e1000762. doi:10.1371/journal.ppat.1000762.
34. Kussie PH, et al. 1996. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274:948-953.
35. Latysheva N, et al. 2006. Syntenin-1 is a new component of tetraspaninenriched microdomains: mechanisms and consequences of the interaction of syntenin-1 with CD63. Mol. Cell. Biol. 26:7707-7718.
36. Lemon SM, Walker C, Alter MJ, Yi M. 2007. Hepatitis C virus, p 1253-1304. In Knipe DM, et al (ed), Fields virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
37. Levy S, Todd SC, Maecker HT. 1998. CD81 (TAPA-1): a molecule involved in signal transduction and cell adhesion in the immune system. Annu. Rev. Immunol. 16:89-109.
38. Lobley A, Whitmore L, Wallace BA. 2002. DICHROWEB: an interactive website for the analysis of protein secondary structure from circular dichroism spectra. Bioinformatics 18:211-212.
39. Masciopinto F, Campagnoli S, Abrignani S, Uematsu Y, Pileri P. 2001. The small extracellular loop of CD81 is necessary for optimal surface expression of the large loop, a putative HCV receptor. Virus Res. 80:1-10.
40. Neugebauer A, Klein CDP, Hartmann RW. 2004. Protein-dynamics of the putative HCV receptor CD81 large extracellular loop. Bioorg. Med. Chem. Lett. 14:1765-1769.
41. Petracca R, et al. 2000. Structure-function analysis of hepatitis C virus envelope-CD81 binding. J. Virol. 74:4824-4830.
42. Pileri P, et al. 1998. Binding of hepatitis C virus to CD81. Science 282:939-941.
43. Rocha-Perugini V, et al. 2008. The CD81 partner EWI-2wint inhibits hepatitis C virus entry. PLoS One 3:e1866. doi:10.1371/journal.pone.0001866.
44. Rubinstein E, et al. 2006. Reduced fertility of female mice lacking CD81. Dev. Biol. 290:351-358.
45. Seigneuret M. 2006. Complete predicted three-dimensional structure of the facilitator transmembrane protein and hepatitis C virus receptor CD81: conserved and variable structural domains in the tetraspanin superfamily. Biophys. J. 90:212-227.
46. Shen Y, Delaglio F, Cornilescu G, Bax A. 2009. TALOS+: a hybrid method for predicting protein backbone torsion angles fromNMRchemical shifts. J. Biomol. NMR 44:213-223.
47. Shuker SB, Hajduk PJ, Meadows RP, Fesik SW. 1996. Discovering high-affinity ligands for proteins: SAR by NMR. Science 274:1531-1534.
48. Stipp CS, Kolesnikova TV, Hemler ME. 2001. EWI-2 is a major CD9 and CD81 partner and member of a novel Ig protein subfamily. J. Biol. Chem. 276:40545-40554.
49. Sugase K, Dyson JH, Wright PE. 2007. Mechanism of coupled folding and binding of an intrinsically disordered protein. Nature 447:1021-1025.
50. Uesugi M, Nyanguile O, Lu H, Levine AJ, Verdine GL. 1997. Induced alpha helix in the VP16 activation domain upon binding to a human TAF. Science 277:1310-1313.
51. VanCompernolle SE, et al. 2003. Small molecule inhibition of hepatitis C virus E2 binding to CD81. Virology 314:371-380.
52. Vranken WF, et al. 2005. The CCPN data model for NMR spectroscopy: development of a software pipeline. Proteins 59:687-696.
53. Wishart DS, Sykes BD. 1994. The 13C chemical-shift index: a simple method for the identification of protein secondary structure using 13C chemical-shift data. J. Biomol. NMR 4:171-180.
54. Yalaoui S, et al. 2008. Hepatocyte permissiveness to Plasmodium infection is conveyed by a short and structurally conserved region of the CD81 large extracellular domain. PLoS Pathog. 4:e1000010. doi:10.1371/ journal.ppat.1000010.
55. Zeisel MB, Fofana I, Fafi-Kremer S, Baumert TF. 2011. Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies. J. Hepatol. 54:566-576.
56. Zhang J, et al. 2004. CD81 is required for hepatitis C virus glycoproteinmediated viral infection. J. Virol. 78:1448-1455.